Anita Vedel Christiansen

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher et al. · Journal of Thrombosis and Haemostasis · 2007 · 984 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Sam Schulman, Ajay K. Kakkar, Samuel Z. Goldhaber et al. · Circulation · 2013 · 932 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Michael Roden, Ludwig Merker, Anita Vedel Christiansen et al. · Cardiovascular Diabetology · 2015 · 134 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker et al. · Clinical Therapeutics · 2015 · 111 citations

Medicine, Pharmacology, Pharmacotherapy +14

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Sam Schulman, Ajay K. Kakkar, Sebastian Schellong et al. · Blood · 2011 · 93 citations

Medicine, Hematology, Pharmacotherapy +12